Stay updated with breaking news from Nasdaq Drrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DURECT (NASDAQ:DRRX – Free Report) had its target price trimmed by HC Wainwright from $32.00 to $27.00 in a report published on Thursday morning, MarketBeat.com reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for DURECT’s Q1 2024 earnings at ($0.39) EPS. Separately, StockNews.com upgraded shares […]
DURECT (NASDAQ:DRRX – Get Free Report) had its target price decreased by research analysts at Cantor Fitzgerald from $44.00 to $41.00 in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. DRRX has been the topic of several […]
DURECT (NASDAQ:DRRX – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday. DURECT Trading Down 0.6 % DRRX opened at $3.16 on Thursday. DURECT has a twelve month low of $2.96 and a twelve month high of $9.70. The firm […]
StockNews.com downgraded shares of DURECT (NASDAQ:DRRX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Wednesday. Separately, HC Wainwright restated a buy rating and issued a $32.00 target price on shares of DURECT in a research note on Tuesday, April 11th. DURECT Trading Down 3.3 […]
StockNews.com cut shares of DURECT (NASDAQ:DRRX – Free Report) from a hold rating to a sell rating in a research report report published on Wednesday morning. Separately, HC Wainwright reiterated a buy rating and issued a $32.00 price objective on shares of DURECT in a report on Tuesday, April 11th. DURECT Price Performance Shares of […]